In Part 1 of our series, we explained the concept of patient steering through Preferred Provider Networks (PPNs). In Part 2, we showed how this behaviour directly harms patients prescribed GLP-1 medications like Ozempic and Wegovy.
But here’s the bigger truth:
(more…)












